All In Biotech

Drug Trial Radar · NCT04552600

Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.

A Randomized, Double-masked, Placebo-controlled Phase 1b/2a Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ in Patients With Non-proliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema.

Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Sep 1, 2019

Primary completion

Aug 10, 2022

Study completion Aug 10, 2022

Sponsor

Lead sponsor
Natureceuticals Sdn BhdIndustry
Sponsor type
Industry
Collaborators
Ministry of Agriculture, Malaysia; Quest International University, Malaysia.; Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia; Universiti Sains Malaysia
First posted
Sep 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults. An ideal adjunctive agent for treating DR hence should be polymorphic and possess antiangiogenic, neuroprotective, anti-inflammatory, anti-oxidant as well as anti-ischaemic properties.Natureceuticals Sdn Bhd assessed the efficacy of core ingredient of Nuvastatic™, Lanctos 75™ for the treatment and management of the diabetic retinopathic condition.

Conditions

  • Diabetic Retinopathy

Interventions

  • NuvastaticDrug

    Phase 1b Interventional, multi-centered, double-masked, randomized

  • PlaceboOther

    Phase 1b Interventional, multi-centered, double-masked, randomized

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate efficacy of Nuvastatic - Retinal ThicknessTime frame: 12 months
  2. To evaluate efficacy of Nuvastatic - protein biomarkersTime frame: 12 months
  3. To evaluate safety of Nuvastatic - Letter ScoreTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fifepoint Multispeciality Hospital Pvt. Ltd.

    Pune, Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.